ESMO Congress 2025 Review — Gynecologic Cancers — Webinar Video Proceedings

Faculty

TARGET AUDIENCE
This program is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the diagnosis and treatment of gynecologic cancers.

LEARNING OBJECTIVES

• Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and as appropriate, counsel patients regarding personalized treatment recommendations.
• Recognize the rationale for targeting folate receptor alpha (FRα) in OC, and understand the mechanism of action of and available research findings with FRα-directed antibody-drug conjugates.
• Appreciate available and emerging clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with platinum-resistant OC, and consider the potential role of this novel therapeutic strategy.
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and optimally incorporate this novel strategy into the care of patients with microsatellite instability-high/mismatch repair (MMR)-deficient and microsatellite-stable/MMR-proficient disease.
• Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
• Interrogate published efficacy and safety findings with anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other local or systemic therapies for cervical cancer (CC), and effectively integrate immune checkpoint inhibition into the care of patients with this disease.
• Review published clinical research documenting the efficacy of HER2-targeted agents and regimens for HER2-overexpressing gynecologic cancers, and consider the role of various approaches in the care of patients with these diseases.
• Describe the scientific justification for, published research data with and current research studies of novel agents and strategies for OC, EC and CC, and effectively prioritize clinical trial opportunities for eligible patients.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/PostESMO25/Gyn/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California

Advisory Committees: AbbVie Inc, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, Merck, Pfizer Inc, Whitehawk Therapeutics; Nonrelevant Financial Relationships: UpToDate.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Merck.

Release date: February 2026
Expiration date: February 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Aghajanian C et al. Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: Final overall survival from DUO-O/ENGOT-ov46/GOG-3025. ESMO 2025;Abstract LBA44.

Akıllı H et al. First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001. ESMO 2025;Abstract 1114P.

Barretina Ginesta MP et al. Final overall survival (OS) results from the randomized double-blind phase III AtTEND/ENGOT-EN7 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. ESMO 2025;Abstract LBA39.

Cibula D et al. Phase 3, randomized, double-blind, placebo (Pbo)-controlled ENGOT-ov43/GOG-3036/KEYLYNK-001 study of 1L chemotherapy (CT) ± pembrolizumab (Pembro) then maintenance (Maint) pembro ± olaparib (Ola) for advanced BRCA-nonmutated epithelial ovarian cancer (EOC): Analysis by HRD status. ESMO 2025; Abstract 1071P.

Clamp AR et al. ICON8B: GCIG phase III randomized trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk Stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysis. ESMO 2025;Abstract 1064O.

Colombo N et al. Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study. ESMO 2025;Abstract LBA3.

Denys H et al. Quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms of disease or toxicity (Q-TWIST) results from the PRIMA/ENGOT-OV26/GOG-3012 final analysis. ESMO 2025;Abstract 1070P.

Eminowicz G et al. GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC). ESMO 2025;Abstract 1221TiP.

Gaba Garcia L et al. Neoadjuvant dostarlimab in mismatch repair deficient (MMRd) stage II-III endometrioid endometrial cancer (EC): The GEICO137-E/NADIA study. ESMO 2025;Abstract 1224TiP.

González-Martín A et al. An open-label, randomized, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line (1L) maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO 01). ESMO 2025;Abstract 127TiP.

Kim SI et al. First-line niraparib maintenance therapy in BRCA wild-type, low-risk advanced ovarian cancer: The POLO trial. ESMO 2025;Abstract 1084P.

Lee J-Y et al. Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1. ESMO 2025;Abstract 145P.

Li N et al. Fuzuloparib (FZPL) monotherapy or in combination with apatinib as first-line maintenance therapy in advanced ovarian cancer: Final analysis of the FZOCUS-1 trial. ESMO 2025;Abstract 1063O.

Makker V et al. Lenvatinib plus pembrolizumab (L + P) vs treatment of physician’s choice (TPC) for advanced endometrial cancer (EC): 5-year outcomes from study 309/KEYNOTE-775. ESMO 2025;Abstract 1119P.

Makker V et al. Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 1 final analysis. ESMO 2025;Abstract 957P.

Moore KN et al. FIRST/ENGOT-OV44 trial: Does the addition of dostarlimab impact niraparib tolerability, exposure, or dose modification? ESMO 2025;Abstract 1101P.

Oaknin A et al. First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer. ESMO 2025;Abstract 1065MO.

Olawaiye AB et al. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): An open-label, randomised, controlled, phase 3 trial. Lancet 2025;405(10496):2205-16. Abstract

Powell MA et al. Post-hoc survival outcomes based on initial and subsequent treatment in patients with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary advanced or recurrent endometrial cancer (pA/R EC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. ESMO 2025;Abstract 1113P.

Ray-Coquard IL. Combining pembrolizumab plus weekly paclitaxel +/- bevacizumab for platinum-resistant recurrent ovarian cancer. ESMO 2025;Abstract Discussant.

Ray-Coquard IL et al. Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01. ESMO 2025;Abstract LBA42.

Slomovitz BM et al. A randomized phase 3 study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY Endometrial 01/GOG-3098/ENGOT-EN24. ESMO 2025;Abstract 1223TiP.

Westin S et al. Durvalumab plus carboplatin/paclitaxel followed by durvalumab for endometrial cancer: Tumour mutational burden-high subpopulation efficacy analyses from the DUO-E trial. ESMO 2025;Abstract 1117P.

Wu X et al. Phase III study of camrelizumab plus famitinib versus platinum-based chemotherapy as first-line therapy for recurrent or metastatic cervical cancer. ESMO 2025;Abstract LBA38.